EGFR and neoplasm: Therefore, the use of medical imaging as a non-invasive method to obtain information about the tumor phenotype could provide clues to predict mutation status of the EGFR gene and has been investigated in several studies (15–17) using positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) to predict the mutation status of EGFR in patients with lung adenocarcinoma; however, the results remain controversial.